CymaBay’s stock surges as Gilead reaches $4.3 billion deal for liver-drug developer

Read Time:6 Second

CymaBay Therapeutics shares jumped 24% early Monday after Gilead Sciences reached a $4.3 billion deal to acquire the liver-drug developer.

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

The timeline for the initial public offering of billionaire investor Bill Ackman’s new investment fund Pershing Square USA appeared to...

U.S. stocks rebounded Friday after a turbulent week for the S&P 500.

Victims of Zelle fraud are entitled to more reimbursement than they’re getting, lawmakers say.

The selloff in U.S. semiconductor and megacap stocks has sucked up most of investors’ attention over the past couple of...

The outage is believed to have caused $5.4 billion in losses for big enterprises — but various factors help insulate...

Shares of DexCom Inc. tumbled more than 40% on Friday and were headed for their worst percentage drop on record,...